Biotech

All Articles

Bicara, Zenas find IPOs to push late-phase assets toward market

.Bicara Therapeutics and Zenas Biopharma have actually supplied new impetus to the IPO market with f...

Genentech to finalize cancer immunology investigation team

.Genentech will certainly close its own cancer cells immunology research study team, as well as unit...

Kezar drops solid cyst however to prove its own worth in period 1 trial

.Kezar Life Sciences is dropping its dim phase 1 solid tumor medicine as the biotech goes all-in on ...

Acelyrin goes down izokibep, lets go 3rd of staff

.Regardless of izokibep keeping its own newly found winning touch in the facility, Acelyrin is no lo...

Rivus' stage 2 obesity-related heart failure trial reaches endpoint

.Rivus Pharmaceuticals has plumped up the potential customers of its fat-busting, muscle-sparing med...

Ovid standstills preclinical job, IV system after soticlestat fail

.Ovid Rehab already disclosed last month that it was actually trimming its own head count as the com...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston ma Port

.Eli Lilly has opened up a $700 thousand R&ampD center in the Boston Seaport, enhancing its RNA and ...

Boundless Bio makes 'modest' discharges five months after $100M IPO

.Only 5 months after protecting a $one hundred thousand IPO, Vast Bio is actually giving up some sta...

Halda's $126M will certainly evolve 'secure and also get rid of' tumor medications

.The first phases of oncology R&ampD may not be short of appealing new methods, and Halda Therapies ...

Lykos 'disappointments' not making known research study infractions along with publisher

.Psychopharmacology has actually drawn three write-ups concerning midstage scientific trial records ...